Prana's PBT2 directly restores neurons critical to cognition

Australia’s Prana Biotechnology (ASX: PBT) has announced the publication of new data on the ability of PBT2 to repair the damage in an Alzheimer's affected brain thereby facilitating the restoration of cognition in Alzheimer's disease (AD).

The findings help to explain the rapid improvement in cognition previously reported in transgenic Alzheimer's mice and in patients in a Phase IIa clinical trial with PBT2. The article published in the science journal PLoS ONE is titled Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease.

The authors led by Paul Adlard, Head of The Synaptic Neurobiology Laboratory at The Mental Health Research Institute, describe the biochemical and anatomical changes occurring in the brains of transgenic Alzheimer's mice treated with PBT2.